Repatha vs Leqvio: Long-Term Durability of Response Explained for Women

What Is the Core Difference Between Repatha and Leqvio?

Both drugs block the PCSK9 pathway to keep LDL receptors working longer and pull more LDL-cholesterol out of your blood. The difference is where in that pathway they act. Repatha is a monoclonal antibody that circulates in your bloodstream and binds PCSK9 protein directly. Leqvio is a small interfering RNA (siRNA) that enters liver cells and silences the gene instruction that makes PCSK9 in the first place. That upstream action is why Leqvio's effect lasts months after a single injection, even though the drug itself clears relatively quickly.

For women managing cardiovascular risk, particularly those who cannot tolerate statins or who need LDL reduction beyond what statins alone provide, both options are on the table. Which one fits your life depends on how fast you need results, how often you are willing to inject, and where you are in your reproductive life.

How Each Drug Works in the Body

Evolocumab (Repatha) circulates as an intact antibody. It has a half-life of roughly 11 to 17 days, which is why the every-two-weeks dosing schedule maintains steady drug levels. Remove PCSK9 protein from circulation and LDL receptors on liver cells recycle to the surface repeatedly instead of being degraded, clearing more LDL with each pass.

Inclisiran (Leqvio) is delivered as a subcutaneous injection and taken up by liver hepatocytes via the ASGR1 receptor. Once inside the cell, it is loaded into the RISC complex and degrades PCSK9 messenger RNA before the protein is ever made. The siRNA molecule persists inside the hepatocyte far longer than its plasma half-life suggests, which is the mechanistic reason a single injection sustains LDL reduction for approximately six months as demonstrated in ORION-10 and ORION-11.

Speed of LDL Lowering

Speed matters clinically. After an acute coronary event or for a woman whose LDL is dangerously high, waiting months for a drug to reach steady state is not ideal. Repatha reduces LDL-C within two weeks of the first injection. Leqvio's maximal effect is not reached until after the second injection at day 90. If rapid LDL lowering is the priority, Repatha has the edge.

Long-Term Durability: What the Trial Data Actually Show

The central question most women and their clinicians ask is whether these drugs keep working. Short-term LDL reductions are common with many therapies; durability over years is rarer and harder to prove.

FOURIER: Five-Year Efficacy Data for Repatha

The FOURIER trial, published in the New England Journal of Medicine in 2017, enrolled 27,564 patients with established atherosclerotic cardiovascular disease on statin therapy. Evolocumab reduced LDL-C by a median of 59 percent compared with placebo, from a baseline median of 92 mg/dL down to 30 mg/dL. The primary endpoint (cardiovascular death, MI, stroke, unstable angina, or revascularization) was reduced by 15 percent over a median 2.2 years of follow-up. In the FOURIER open-label extension, which followed patients for up to five years, LDL lowering was maintained without attenuation of effect and with no new safety signals.

Women made up approximately 25 percent of FOURIER participants. That under-representation is a genuine evidence gap. The trial did not report sex-stratified cardiovascular outcomes with sufficient statistical power to draw firm conclusions about whether women's absolute risk reduction differs from men's.

ORION-10 and ORION-11: Three-Year Durability for Leqvio

The key phase 3 trials for inclisiran, ORION-10 and ORION-11, published together in NEJM in 2020, enrolled 1,561 and 1,617 patients respectively. Both trials required existing cardiovascular disease or high-risk equivalents with elevated LDL-C despite maximally tolerated statin therapy. The time-averaged LDL-C reduction over 17 months was approximately 52 to 54 percent versus placebo, with a 50 percent reduction still sustained at month 17 in both trials.

A key durability finding: the LDL-lowering effect at month 17 was nearly identical to the effect at month 3 after steady state was established. The drug did not wear off. Longer follow-up from the ORION-3 and ORION-8 extension studies confirms durable LDL suppression at four years, with no evidence of tachyphylaxis.

Women constituted roughly 28 percent of ORION-10 and 25 percent of ORION-11. Female-specific subgroup analyses showed consistent LDL reductions, though, as with FOURIER, the trials were not powered to demonstrate sex-specific cardiovascular outcome differences.

A practical framework for comparing durability:

| Feature | Repatha (evolocumab) | Leqvio (inclisiran) | |---|---|---| | Time to maximal LDL reduction | 2-4 weeks | ~90 days (after 2nd dose) | | Duration of LDL suppression per dose | 2-4 weeks | ~6 months | | Evidence of sustained efficacy | Up to 5 years (FOURIER OLE) | Up to 4 years (ORION-8) | | LDL rebound if dose missed | Rapid (within weeks) | Gradual (weeks to months) | | Injection frequency at maintenance | Every 2 weeks or monthly | Twice yearly | | Women's proportion in key trials | ~25% (FOURIER) | ~25-28% (ORION-10/11) |

How These Drugs Interact With Women's Hormones and Life Stages

Reproductive Years (Ages 18-40)

In premenopausal women, LDL levels are generally lower than in age-matched men, partly because estrogen upregulates LDL receptor expression. Women with familial hypercholesterolemia (FH), PCOS-related dyslipidemia, or early cardiovascular disease may still require PCSK9 inhibition during reproductive years. Both Repatha and Leqvio are options, but contraception requirements apply (see pregnancy section below).

Women with PCOS frequently have elevated LDL and low HDL as part of a broader metabolic picture. Neither evolocumab nor inclisiran has been studied specifically in women with PCOS, so any LDL-lowering benefit in this group is extrapolated from broader high-risk trial populations, not directly demonstrated.

Perimenopause (Typically Ages 45-55)

Perimenopause is a critical window for cardiovascular risk in women. As estrogen declines, LDL-C rises, often by 10 to 14 mg/dL above premenopausal baseline, and small, dense LDL particles increase in proportion. A woman who was managing adequately on a statin during her 40s may find her LDL suddenly out of target in perimenopause without any change in diet or medication. This is when a PCSK9 inhibitor addition becomes clinically relevant.

Neither Repatha nor Leqvio has been studied in trials designed specifically for perimenopausal women. The FOURIER and ORION trials enrolled predominantly postmenopausal women in the female subgroup by virtue of the mean age of female participants (approximately 62 years in FOURIER). Perimenopause-specific pharmacokinetic data do not exist for either drug.

Post-Menopause

The absolute cardiovascular risk in postmenopausal women rises substantially, and this is where the clearest trial data apply. Most female participants in FOURIER, ORION-10, and ORION-11 were postmenopausal. LDL lowering appears equally effective regardless of menopausal status based on available subgroup data, though these analyses are exploratory and not powered for definitive conclusions.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know

Both Repatha and Leqvio are contraindicated in pregnancy. This is not a precautionary statement based on theoretical risk alone.

Repatha (Evolocumab) in Pregnancy

Animal reproductive studies with evolocumab showed no direct fetal harm at clinical doses, but PCSK9 plays a role in fetal cholesterol metabolism. Cholesterol is essential for fetal neural and adrenal development. The FDA prescribing information advises discontinuing Repatha when pregnancy is recognized and notes that maternal hypocholesterolemia during fetal development carries theoretical risk. There are no adequate and well-controlled studies in pregnant women. Repatha is classified as a drug for which human pregnancy data are insufficient to determine risk.

Women of reproductive age prescribed Repatha should use effective contraception for the duration of treatment.

Leqvio (Inclisiran) in Pregnancy

Inclisiran's mechanism, silencing gene expression in liver cells, raises the question of off-target RNA effects. Animal studies showed embryo-fetal toxicity at doses substantially above the human therapeutic dose. There are no human pregnancy data. The FDA label states that inclisiran should not be used during pregnancy and that women of childbearing potential should use effective contraception. Because inclisiran persists in hepatocytes for months after a dose, conception during the dosing interval is a real consideration. A woman planning pregnancy should discuss timing with her clinician well before the next injection.

Lactation

Neither evolocumab nor inclisiran has human data on transfer into breast milk. Animal studies have not found evidence of lactation-related harm, but given the absence of human lactation data and the non-essential nature of aggressive LDL lowering during the postpartum period for most women, both drugs are generally paused during breastfeeding. Discuss the decision with your care team; statin therapy is also contraindicated in lactation, which narrows options for women with FH or very high-risk cardiovascular status postpartum.

Contraception Guidance

Women who need PCSK9 inhibition during reproductive years should use highly effective contraception (IUD, implant, or hormonal methods) while on either drug. If pregnancy is desired, Repatha should be stopped before attempting conception. For Leqvio, the six-month duration of effect per dose means planning needs to account for the interval since the last injection; consult your clinician about washout timing given that hepatocyte persistence is not fully characterized in terms of fetal risk.

Who This Is Right For and Who Should Choose Differently

Repatha May Fit You Better If:

• You need rapid LDL lowering (post-acute coronary syndrome, very high baseline LDL)
• You want the flexibility to stop the drug and have LDL recover within weeks if life circumstances change (pregnancy planning, side effect concerns)
• You are comfortable with more frequent self-injection (every two weeks) or prefer monthly clinic visits for the 420 mg dose
• You have familial hypercholesterolemia and need the deepest possible LDL reduction: evolocumab was specifically studied in FH in the TESLA Part B trial

Leqvio May Fit You Better If:

• Adherence to frequent injections has been a barrier with other therapies
• Your clinician administers the injection in-office, removing the self-injection requirement entirely
• You are postmenopausal, cardiovascular risk is elevated, and you want a low-burden maintenance regimen
• You are not in a phase of life where pregnancy is a near-term possibility

Neither Drug Is Appropriate If:

• You are pregnant or actively trying to conceive
• You are breastfeeding
• Your LDL elevation responds adequately to maximally tolerated statins plus ezetimibe

Should You Switch From Repatha to Leqvio?

Switching is medically reasonable and increasingly common as Leqvio's availability and in-office administration model make it appealing for women who struggle with adherence to biweekly self-injection. The clinical question is how to manage the transition.

The Transition Window Problem

Repatha's LDL-lowering effect dissipates within two to four weeks of stopping. Leqvio reaches its maximal effect after the second injection at day 90. If you stop Repatha and immediately start Leqvio (day 0 injection), your LDL will be suppressed on day 0 by the first Leqvio dose, but not to the same degree as it would be at month 3. Expect your LDL to be partially elevated during the transition window, roughly from weeks 2 to 8, before Leqvio's effect accumulates.

A pragmatic approach used in some clinical practices: give Leqvio day-0 injection within the last two weeks of the final Repatha dose, so the siRNA is loading into hepatocytes while evolocumab is still partially active. This overlapping strategy has not been tested in a randomized trial and represents clinical extrapolation from the pharmacokinetics of both drugs.

Monitoring After the Switch

Check a fasting lipid panel at approximately 90 days after the first Leqvio injection (just before or at the second injection visit) to confirm LDL-C is at target. If LDL is not adequately controlled at that visit, the second Leqvio dose at day 90 will push the effect further; recheck at month 6. Do not judge Leqvio's durability from an LDL checked in the first four weeks after transitioning.

Cost and Coverage Considerations for Women

Both drugs carry list prices above $5,000 per year in the US before insurance. Patient assistance programs exist for both. For women on Medicare, the Inflation Reduction Act drug price negotiation provisions may affect PCSK9 inhibitor pricing in coming years. Check your plan's specialty tier and step-therapy requirements; many insurers require documented statin intolerance or failure, plus ezetimibe trial, before approving either drug.

Side Effects: What Women Report

The safety profiles of both drugs are favorable compared with statins, which is relevant for women who disproportionately experience statin myopathy. In FOURIER, injection-site reactions occurred in 2.1 percent of evolocumab patients versus 1.6 percent of placebo, with no significant excess of muscle-related adverse events. In ORION-10 and ORION-11, injection-site reactions with inclisiran occurred in 2.6 percent of patients versus 0.9 percent of placebo; reactions were mostly mild and transient.

Neurocognitive side effects were a concern raised with PCSK9 inhibitors early in their development. The EBBINGHAUS sub-study of FOURIER found no significant difference in neurocognitive function between evolocumab and placebo over two years. Inclisiran lacks a comparably powered neurocognitive sub-study.

Women in FOURIER reported similar types of adverse events to men in the available published data, but sex-disaggregated adverse event tables were not published in the primary paper. This is an evidence gap that reflects a broader pattern in cardiovascular trial reporting.

The Evidence Gap: What We Still Do Not Know for Women

Honesty about evidence limitations is part of good clinical practice. Here is what remains genuinely unknown or under-studied for women:

• Cardiovascular outcome data in women specifically: Neither FOURIER nor the ORION outcomes trial (ORION-4, which is ongoing) will have adequate power for sex-stratified hard-outcome analysis in women alone.
• Pharmacokinetics in perimenopause: No dedicated PK studies exist for either drug across the menopausal transition. The hormonal shift that changes LDL burden in perimenopause has not been studied in relation to PCSK9 inhibitor drug exposure or efficacy.
• PCOS: No trial has enrolled women with PCOS as a primary population for either drug.
• Postpartum dyslipidemia: Both drugs are paused in pregnancy, leaving women with FH or very high cardiovascular risk without good PCSK9 options in the postpartum period if they breastfeed.
• Interaction with hormonal contraception or menopausal hormone therapy: Neither drug is known to interact with estrogen or progestins, but formal interaction studies are absent from the published literature.

Talking to Your Clinician: Questions Worth Asking

Before your next appointment, consider asking:

• Is my LDL-C above target despite statin plus ezetimibe, and if so, which PCSK9 inhibitor is covered by my insurer?
• Given where I am in my reproductive life, which drug's dosing schedule and contraception requirements make more sense for me?
• If I switch from Repatha to Leqvio, when should we check my LDL again?
• What is my actual 10-year ASCVD risk score, and does adding a PCSK9 inhibitor meaningfully change my absolute risk?

Your clinician can calculate your 10-year ASCVD risk using the ACC/AHA Pooled Cohort Equations, which include sex as a variable and produce a female-specific estimate.